International Journal of Scientific Research and Management (IJSRM)
||Volume||14||Issue||01||Pages||2419-2421||2026||
Website: https://ijsrm.net ISSN (e): 2321-3418
DOI: 10.18535/ijsrm/v14i01.mp03

Targeting the Mitochondrial Permeability Transition Pore: A Translational Approach to Prevent Myocardial Reperfusion Injury in Delayed Percutaneous Coronary Intervention

İlyas Mammadyarov[1], Babak Bahrami[2]

Abstract
Timely revascularization is the cornerstone of limiting ischemic cell death in acute myocardial infarction (MI) (1). However, delayed percutaneous coronary intervention (PCI) paradoxically poses a significant threat to the myocardium, leading to lethal reperfusion injury—a major clinical problem contributing to adverse outcomes despite successful epicardial reperfusion (2). Microvascular injury resulting from delayed reperfusion, first documented in the 1960s, significantly exacerbates myocardial injury (3). The pathogenesis of lethal reperfusion injury is driven by three central paradoxes: the calcium paradox, involving a pathological surge in intracellular calcium; the oxygen paradox, characterized by a burst of reactive oxygen species (ROS); and the pH paradox, marked by the rapid normalization of intracellular pH (4). These converge to induce mitochondrial permeability transition pore (MPTP) opening, resulting in mitochondrial damage and cardiomyocyte death (5). Despite elucidation of these mechanisms in experimental models, translation to clinical cardioprotection has been challenging (6). This review explores the mechanistic pathways of reperfusion injury, discusses the failures and promises of therapeutic strategies, and highlights future translational directions for protecting the myocardium in the context of delayed PCI. Therefore, overcoming translational challenges by developing targeted combination therapies and refining patient selection based on individual pathophysiology is the crucial next step to harness the therapeutic potential of MPTP inhibition and significantly improve outcomes in delayed PCI (7).

Keywords: Myocardial Reperfusion Injury, Mitochondrial Permeability Transition Pore, Percutaneous Coronary Intervention, Microvascular Obstruction, Cardioprotection, Ischemic Conditioning, Cyclosporine, Translational Medical Research

Introduction

The cornerstone therapy for reducing ischemic burden and limiting infarct size in patients with acute myocardial infarction is timely reperfusion, primarily through primary percutaneous coronary intervention (PPCI) (8). The efficacy of this strategy is overwhelmingly dependent on its prompt application (9). Any significant delay not only diminishes the benefit of salvaging ischemic myocardium but also instigates reperfusion injury—a phenomenon that inflicts severe damage upon previously viable cardiac tissue (10). Despite successful restoration of epicardial blood flow with PPCI, a significant proportion of patients experience suboptimal myocardial recovery due to microvascular dysfunction and reperfusion injury, which are independent predictors of adverse ventricular remodeling and worse long-term prognosis (11). This review focuses on the mechanisms underlying this injury and the translational potential of targeting them.

Discussion

Evolution of MI Treatment and the Reperfusion Era The treatment of MI has evolved from strict bed rest to the modern reperfusion era(12). The current phase is defined by PPCI and advanced antithrombotic therapy (13). However, the critical caveat of this life-saving strategy is the stringent requirement for timeliness (14).

Delayed angioplasty, while mitigating ultimate cell death, can concurrently inflict damage on the healthy myocardium—a paradox known as reperfusion injury (2).

Forms of Reperfusion Injury Myocardial injury secondary to delayed reperfusion manifests in four principal forms:

1. Reperfusion Arrhythmias: Often self-limiting (15).
2. Myocardial Stunning: Reversible post-ischemic dysfunction (16).
3. Microvascular Obstruction: Irreversible damage preventing tissue perfusion (11).
4. Lethal Myocardial Reperfusion Injury: Death of viable cardiomyocytes due to reperfusion itself (17).

The Core Mechanisms: The Three Paradoxes and MPTP The pathogenesis of lethal injury is underpinned by three biochemical paradoxes that trigger MPTP opening:

- The Calcium Paradox: Massive cytosolic calcium influx (18).
- The Oxygen Paradox: Burst of ROS from sudden reintroduction of oxygen (19).
- The pH Paradox: Rapid washout of acidosis, removing the protective acidic inhibition (20).

The cessation of oxidative phosphorylation during ischemia leads to ATP depletion, failure of ion pumps, and intracellular acidosis (21). The low pH during ischemia paradoxically protects the cell by inhibiting MPTP opening (22). Upon reperfusion, the rapid correction of acidosis via the Na+/H+ exchanger (NHE) increases intracellular Na+ load, which is then exchanged for Ca2+ via the Na+/Ca2+ exchanger (NCX) operating in reverse mode, leading to catastrophic calcium overload (23). The simultaneous reactivation of oxidative phosphorylation generates a burst of ROS, which further damages cellular components and promotes MPTP opening (19). The resultant mitochondrial swelling and rupture release pro-death factors, ensuring cardiomyocyte death (17).



Figure 1: Core Mechanism of Lethal Reperfusion Injury

The Combined Impact on Infarct Size The combined effect of ischemic and reperfusion injury determines the final infarct size(25). While PPCI aims to limit infarct size by abolishing ischemia, concomitant reperfusion injury counteracts this benefit (17). Adjunctive therapies targeting reperfusion injury, applied

alongside timely PPCI, could shift the outcome closer to the theoretical minimum, maximizing myocardial salvage (26).

Time-Dependent Progression of Tissue Damage The progression of tissue damage is time-dependent(9). Timely PPCI can salvage the ischemic and injured areas before irreversible necrosis sets in (27). If reperfusion is delayed, the necrotic core expands, and the mechanisms of reperfusion injury accelerate the death of jeopardized myocardial regions, leading to a larger final infarct (28). The end result is the replacement of functional myocardium with non-contractile scar tissue, predisposing patients to heart failure and arrhythmias (29).



Figure 2: Impact of Reperfusion Timing on Final Infarct Size

Protective Strategies and Current Translational Challenges Various strategies to limit reperfusion injury have been investigated.

- Non-Pharmacological: Ischemic postconditioning and remote ischemic conditioning have shown cardioprotective effects in experimental settings by delaying MPTP opening, but their clinical efficacy has been variable (30).
- Pharmacological: MPTP inhibitors like cyclosporine A showed initial promise but failed to consistently improve outcomes in larger clinical trials (e.g., CIRCUS trial) (31). Other agents, such as sodium-hydrogen exchanger (NHE) inhibitors and antioxidants, have also yielded limited clinical benefits, reflecting the multifactorial and complex pathophysiology of reperfusion injury in humans with comorbidities (32).

Advanced imaging techniques like cardiac MRI with feature tracking are crucial for identifying patients with microvascular obstruction who might benefit most from future therapies, enabling better patient stratification (33).

Future Perspectives And Translational Challenges

The translation of cardioprotective strategies from bench to bedside has been largely disappointing (6). This gap is attributed to several factors:

1. Experimental vs. Clinical Conditions: Animal models often use young, healthy subjects without the comorbidities (diabetes, hypertension) or comedications (e.g., P2Y12 inhibitors, statins) that characterize human MI patients and which may influence the response to therapy (34).
2. Lack of Robust Biomarkers: The inability to precisely identify patients experiencing significant reperfusion injury prior to intervention hinders targeted therapy (35).
3. Therapeutic Timing and Specificity: The therapeutic window for many agents is narrow, and non-specific drugs like cyclosporine may have off-target effects (36).

Future research should focus on:

- Developing Novel Therapeutic Agents: Discovering more specific and potent MPTP inhibitors without immunosuppressive effects is a priority (37).
- Exploring Combination Therapies: Targeting multiple pathways simultaneously (e.g., ROS burst + calcium overload) may be necessary to overcome the redundancy of injury mechanisms (26).
- Improving Clinical Trial Design: Future trials must incorporate improved patient selection using advanced imaging biomarkers (e.g., cardiac MRI to confirm microvascular obstruction) and target earlier phases of care (38).
- Exploring Non-Invasive Strategies: Optimizing remote ischemic conditioning protocols and exploring their combination with pharmacological agents could offer a practical approach (39).

Conclusion

Emergency angioplasty for acute MI is a time-critical intervention (8). Delays activate pathological pathways that cause preventable reperfusion injury (2). Minimizing this injury is crucial for improving clinical outcomes (17). While understanding the mechanisms of MPTP opening has provided valuable insights, overcoming translational challenges is the next critical step (6). Therefore, public education, efficient pre-hospital systems, and in-hospital protocols ensuring rapid diagnosis and PCI are paramount (9). Furthermore, the future of cardioprotection likely lies in personalized, combinatorial approaches based on individual risk stratification and a deeper understanding of the human pathophysiology of reperfusion injury (40).

References

1. Ibanez B, et al. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015;65(14):1454-1471.
2. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121-1135.
3. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. Am Heart J. 1985;109(2):305-318.
4. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol. 2003;35(4):339-341.
5. Halestrap AP, Richardson AP. The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury. J Mol Cell Cardiol. 2015;78:129-141.
6. Hausenloy DJ, et al. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2013;98(1):7-27.
7. Ong SB, et al. Inhibiting Mitochondrial Fission Protects the Heart Against Ischemia/Reperfusion Injury. Circulation. 2010;121(18):2012-2022.
8. O'Gara PT, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2013;61(4):e78-e140.
9. Terkelsen CJ, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA. 2010;304(7):763-771.
10. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword?. J Clin Invest. 1985;76(5):1713-1719.
11. Niccoli G, et al. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54(4):281-292.
12. Anderson JL, Morrow DA. Acute Myocardial Infarction. N Engl J Med. 2017;376(21):2053-2064.
13. Levine GN, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. J Am Coll Cardiol. 2016;68(10):1082-1115.
14. Bøtker HE, et al. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol. 2018;113(5):39.
15. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev. 1989;69(4):1049-1169.
16. Bolli R, Marbán E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev. 1999;79(2):609-634.

17. Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol. 2020;17(12):773-789.
18. García-Dorado D, et al. Calcium-mediated cell death during myocardial reperfusion. Cardiovasc Res. 2012;94(2):168-180.
19. Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res. 2006;70(2):181-190.
20. Cohen MV, Downey JM. Ischaemic postconditioning: from bench to bedside. Cardiovasc Res. 2008;79(1):3-4.
21. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008;88(2):581-609.
22. Halestrap AP. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem Soc Trans. 2006;34(Pt 2):232-237.
23. Avkiran M, Marber MS. Na(+)/H(+) exchange inhibitors for cardioprotective therapy: progress, problems and prospects. J Am Coll Cardiol. 2002;39(5):747-753.
24. Gustafsson ÅB, Gottlieb RA. Heart mitochondria: gates of life and death. Cardiovasc Res. 2008;77(2):334-343.
25. Reffelmann T, Kloner RA. The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol. 2006;101(5):359-372.
26. Hausenloy DJ, Yellon DM. Ischaemic conditioning and reperfusion injury. Nat Rev Cardiol. 2016;13(4):193-209.
27. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56(5):786-794.
28. Braunwald E. The treatment of acute myocardial infarction: the past, the present, and the future. Eur Heart J Acute Cardiovasc Care. 2012;1(1):9-12.
29. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81(4):1161-1172.
30. Hausenloy DJ, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. Lancet. 2019;394(10207):1415-1424.
31. Cung TT, et al. Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med. 2015;373(11):1021-1031.
32. Lincoff AM, et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Circulation. 2000;102(25):3032-3038.
33. Eitel I, et al. Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation myocardial infarction. Circ Cardiovasc Imaging. 2011;4(4):354-362.
34. Ferdinandy P, et al. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014;66(4):1142-1174.
35. Garcia-Dorado D, et al. Novel therapeutic strategies for the management of myocardial ischemia/reperfusion injury: where are we going?. Trends Cardiovasc Med. 2017;27(1):1-7.
36. Argaud L, et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol. 2005;38(2):367-374.
37. Elrod JW, Molkentin JD. Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. Circ J. 2013;77(5):1111-1122.
38. White SK, et al. Measuring myocardial salvage. Cardiovasc Res. 2012;94(2):266-275.
39. Heusch G, et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014;383(9932):1933-1943.
40. Davidson SM, et al. Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(1):89-99.